Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells

Neuroendocrinology

Volumn 103, Issue 6, 2016, Pages 724-737

  Avniel Polak, Shani ^a   Leibowitz, Gil ^a   Riahi, Yael ^a   Glaser, Benjamin ^a   Gross, David J ^a   Grozinsky Glasberg, Simona ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Autophagy; Chloroquine; mTOR inhibitors; Neuroendocrine cells

Indexed keywords

CASPASE 3; CHLOROQUINE; DACTOLISIB; EVEROLIMUS; KI 67 ANTIGEN; LIPOCORTIN 5; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SMALL INTERFERING RNA; TORIN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MAP1LC3B PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; MTOR PROTEIN, HUMAN; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; STAINING; TUMOR CELL; WESTERN BLOTTING; XTT ASSAY; ANTAGONISTS AND INHIBITORS; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; TIME FACTOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHLOROQUINE; EVEROLIMUS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; KI-67 ANTIGEN; MICROTUBULE-ASSOCIATED PROTEINS; NEUROENDOCRINE TUMORS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84949604289     PISSN: 00283835     EISSN: 14230194     Source Type: Journal    
DOI: 10.1159/000442589     Document Type: Article

References (50)

1. Oberg K: Neuroendocrine tumors of the gastrointestinal tract: recent advances in molecular genetics, diagnosis, and treatment. Curr Opin Oncol 2005; 17: 386-391.
2. Oberg K: Neuroendocrine tumors: recent progress in diagnosis and treatment. Endocr Relat Cancer 2011; 18(suppl 1):E3-E6.
3. Grozinsky-Glasberg S, Grossman AB, Korbonits M: The role of somatostatin analogues in the treatment of neuroendocrine tumours. Mol Cell Endocrinol 2008; 286: 238-250.
4. Altomare DA, Testa JR: Perturbations of the AKT signaling pathway in human cancer. Oncogene 2005; 24: 7455-7464.
5. Grozinsky-Glasberg S, Pavel M: Inhibition of mTOR in carcinoid tumors. Target Oncol 2012; 7: 189-195.
6. Grozinsky-Glasberg S, Franchi G, Teng M, Leontiou CA, Ribeiro de Oliveira A Jr, Dalino P, Salahuddin N, Korbonits M, Grossman AB: Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell line. Neuroendocrinology 2008; 87: 168-181.
7. Zitzmann K, De Toni EN, Brand S, Goke B, Meinecke J, Spottl G, Meyer HH, Auernhammer CJ: The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells. Neuroendocrinology 2007; 85: 54-60.
8. Yang ZJ, Chee CE, Huang S, Sinicrope FA: The role of autophagy in cancer: therapeutic implications. Mol Cancer Ther 2011; 10: 1533-1541.
9. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K: RAD001 in advanced neuroendocrine tumors: everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
10. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378: 2005-2012.
11. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N: mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-1508.
12. Feldman ME, Apsel B, Uotila A, Loewith R, Knight ZA, Ruggero D, Shokat KM: Activesite inhibitors of mTOR target rapamycinresistant outputs of mTORC1 and mTORC2. PLoS Biol 2009; 7:e38.
13. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS: Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl) phenyl)-9-(quinolin-3-yl)benzo[h][1,6] naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. J Med Chem 2010; 53: 7146-7155.
14. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, Wang S, Garcia-Echeverria C, Maira SM: Specific apoptosis induction by the dual PI3K/mTOR inhibitor NVP-BEZ235 in HER2 amplified and PIK-3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009; 106: 22299-22304.
15. Rubinsztein DC, Codogno P, Levine B: Autophagy modulation as a potential therapeutic target for diverse diseases. Nat Rev Drug Discov 2012; 11: 709-730.
16. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, Kundu M, Kim DH: ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009; 20: 1992-2003.
17. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, Sabatini DM: Deptor is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 2009; 137: 873-886.
18. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, Miura Y, Iemura S, Natsume T, Takehana K, Yamada N, Guan JL, Oshiro N, Mizushima N: Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol Biol Cell 2009; 20: 1981-1991.
19. Ganley IG, Lam du H, Wang J, Ding X, Chen S, Jiang X: ULK1 · ATG13 · FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem 2009; 284: 12297-12305.
20. Bachar-Wikstrom E, Wikstrom JD, Kaiser N, Cerasi E, Leibowitz G: Improvement of ER stress-induced diabetes by stimulating autophagy. Autophagy 2013; 9: 626-628.
21. Yang Z, Klionsky DJ: Mammalian autophagy: core molecular machinery and signaling regulation. Curr Opin Cell Biol 2010; 22: 124-131.
22. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med 2010; 16: 205-213.
23. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, Gao Y, Reichling LJ, Sim T, Sabatini DM, Gray NS: An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 2009; 284: 8023-8032.
24. Degtyarev M, De Maziere A, Orr C, Lin J, Lee BB, Tien JY, Prior WW, van Dijk S, Wu H, Gray DC, Davis DP, Stern HM, Murray LJ, Hoeflich KP, Klumperman J, Friedman LS, Lin K: Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol 2008; 183: 101-116.
25. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, Haas-Kogan D, James CD, Oakes SA, Debnath J, Shokat KM, Weiss WA: Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010; 3:ra81.
26. Xu CX, Zhao L, Yue P, Fang G, Tao H, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY: Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther 2011; 12: 549-555.
27. Seitz C, Hugle M, Cristofanon S, Tchoghandjian A, Fulda S: The dual PI3K/mTOR inhibitor NVP-BEZ235 and chloroquine synergize to trigger apoptosis via mitochondrial-lysosomal cross-talk. Int J Cancer 2013; 132: 2682-2693.
28. Amaravadi RK, Yu D, Lum JJ, Bui T, Christophorou MA, Evan GI, Thomas-Tikhonenko A, Thompson CB: Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest 2007; 117: 326-336.
29. Weckman A, Rotondo F, Di Ieva A, Syro LV, Butz H, Cusimano MD, Kovacs K: Autophagy in endocrine tumors. Endocr Relat Cancer 2015; 22:R205-R218.
30. Hong SK, Kim JH, Starenki D, Park JI: Autophagy sensitivity of neuroendocrine lung tumor cells. Int J Oncol 2013; 43: 2031-2038.
31. Mizushima N, Yoshimori T: How to interpret LC3 immunoblotting. Autophagy 2007; 3: 542-545.
32. Kabeya Y, Mizushima N, Yamamoto A, Oshitani-Okamoto S, Ohsumi Y, Yoshimori T: LC3, GABARAP and GATE16 localize to autophagosomal membrane depending on form-II formation. J Cell Sci 2004; 117: 2805-2812.
33. Ichimura Y, Kirisako T, Takao T, Satomi Y, Shimonishi Y, Ishihara N, Mizushima N, Tanida I, Kominami E, Ohsumi M, Noda T, Ohsumi Y: A ubiquitin-like system mediates protein lipidation. Nature 2000; 408: 488-492.
34. Wu J, Dang Y, Su W, Liu C, Ma H, Shan Y, Pei Y, Wan B, Guo J, Yu L: Molecular cloning and characterization of rat LC3A and LC3B-two novel markers of autophagosome. Biochem Biophys Res Commun 2006; 339: 437-442.
35. Tanida I, Ueno T, Kominami E: Human light chain 3/MAP1LC3B is cleaved at its carboxylterminal Met121 to expose Gly120 for lipidation and targeting to autophagosomal membranes. J Biol Chem 2004; 279: 47704-47710.
36. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, Kominami E, Ohsumi Y, Yoshimori T: LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-5728.
37. He H, Dang Y, Dai F, Guo Z, Wu J, She X, Pei Y, Chen Y, Ling W, Wu C, Zhao S, Liu JO, Yu L: Post-translational modifications of three members of the human MAP1LC3 family and detection of a novel type of modification for MAP1LC3B. J Biol Chem 2003; 278: 29278-29287.
38. Balic A, Sorensen MD, Trabulo SM, Sainz B Jr, Cioffi M, Vieira CR, Miranda-Lorenzo I, Hidalgo M, Kleeff J, Erkan M, Heeschen C: Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol Cancer Ther 2014; 13: 1758-1771.
39. Kim J, Yip ML, Shen X, Li H, Hsin LY, Labarge S, Heinrich EL, Lee W, Lu J, Vaidehi N: Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PLoS One 2012; 7:e31004.
40. Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion AC, Radtke F, Boulanger C, Gerhardt H, Dejana E, Dewerchin M, Ghesquiere B, Annaert W, Agostinis P, Carmeliet P: Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 2014; 26: 190-206.
41. Xue J, Moyer A, Peng B, Wu J, Hannafon BN, Ding WQ: Chloroquine is a zinc ionophore. PLoS One 2014; 9:e109180.
42. Klionsky DJ: The correct way to monitor autophagy in higher eukaryotes. Autophagy 2005; 1: 65.
43. Lamoureux F, Thomas C, Crafter C, Kumano M, Zhang F, Davies BR, Gleave ME, Zoubeidi A: Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. Clin Cancer Res 2013; 19: 833-844.
44. Shinojima N, Yokoyama T, Kondo Y, Kondo S: Roles of the Akt/mTOR/p70S6K and ERK1/2 signaling pathways in curcumininduced autophagy. Autophagy 2007; 3: 635-637.
45. Bachar-Wikstrom E, Wikstrom JD, Ariav Y, Tirosh B, Kaiser N, Cerasi E, Leibowitz G: Stimulation of autophagy improves endoplasmic reticulum stress-induced diabetes. Diabetes 2013; 62: 1227-1237.
46. Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, Metivier D, Meley D, Souquere S, Yoshimori T, Pierron G, Codogno P, Kroemer G: Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005; 25: 1025-1040.
47. Gonzalez-Polo RA, Boya P, Pauleau AL, Jalil A, Larochette N, Souquere S, Eskelinen EL, Pierron G, Saftig P, Kroemer G: The apoptosis/ autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005; 118: 3091-3102.
48. Laplante M, Sabatini DM: mTOR signaling in growth control and disease. Cell 2012; 149: 274-293.
49. Grozinsky-Glasberg S, Shimon I, Rubinfeld H: The role of cell lines in the study of neuroendocrine tumors. Neuroendocrinology 2012; 96: 173-187.
50. Shor B, Gibbons JJ, Abraham RT, Yu K: Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009; 8: 3831-3837.